Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

Lundbeck may buy GSK drugs to complement portfolio: Sydbank

October 15, 2014
Life sciences
(Reuters) – Danish pharmaceutical group Lundbeck (LUN.CO) is one of the potential bidders for some of the older products worth in total $3 billion that British GlaxoSmithKline (GSK.L) is looking to divest, according to sources.
 
Lundbeck is reviewing a bid for products marketed in North America as it seeks to expand there, two sources told Reuters.
 
Shares in Lundbeck are traded 2.1 percent higher on Wednesday at 1045 GMT (0645 EDT) outperforming a 0.6 percent fall in the Danish benchmark index .OMXC20CAP.
 
Analysts made the following comments:
 
ANALYST SOREN LONTOFT HANSEN, SYDBANK
 
“Lundbeck could be looking at drugs that could complement its existing drug portfolio. We have seen that before, for example when the company bought Chelsea Therapeutics International, whose neurodrug Northera had just been approved in the United States.
 
“The patents expire on some of Lundbeck’s most significant products these years. The company has some of its own developed products as Selincro and Brintellix, and with the Japanese partner Otsuka it has Abilify Maintena. But it takes time to penetrate the market for these drugs, so I think Lundbeck is also looking for alternatives which can complement the existing pipeline, and where it makes sense for their salesmen also to have these drugs with them, when they visit customers”.
 
“Lundbeck has built a decent business in North America on drugs for some relatively rare diseases and they are still building on that what with Abilify Maintena and Brintellix”.
 
“There’s a giant potential on the U.S. market. It makes sense to use the existing sales force to take on a few more drugs. So it will probably be some drugs that complements some of Lundbeck’s existing drugs.”
 
(Reporting by Teis Jensen; editing by Sabina Zawadzki)

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach